<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335458">
  <stage>Registered</stage>
  <submitdate>10/05/2010</submitdate>
  <approvaldate>11/05/2010</approvaldate>
  <actrnumber>ACTRN12610000378022</actrnumber>
  <trial_identification>
    <studytitle>Effect of metformin on lung function in diabetic or prediabetic individuals with respiratory disease</studytitle>
    <scientifictitle>The effect of oral metformin on spirometry, exercise capacity and quality of life in adults with chronic obstructive pulmonary disease (COPD) and either diet-controlled type 2 diabetes mellitus or impaired glucose tolerance.</scientifictitle>
    <utrn>U1111-1114-9527</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic obstructive pulmonary disease</healthcondition>
    <healthcondition>Type 2 diabetes mellitus</healthcondition>
    <healthcondition>Impaired glucose tolerance</healthcondition>
    <healthcondition>Insulin resistance</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral metformin 850mg twice daily for 6 months.</interventions>
    <comparator>Not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in forced expiratory volume in first second (FEV1), measured using spirometer</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks, 18 weeks, 24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in incremental shuttle walk distance</outcome>
      <timepoint>Baseline and 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change in respiratory quality of life score (St George Respiratory questionnaire)</outcome>
      <timepoint>Baseline and 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>*	Obese (body mass index &gt; 30)
*	Central pattern of obesity (elevated waist circumference)
*	Impaired glucose tolerance or diet-controlled type 2 diabetes mellitus (previous diagnosis, or evidence of blood tests meeting American Diabetes Association 2010 criteria)
*	Post-bronchodilator spirometry that is consistent with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2+ COPD 
*	Symptomatic: Medical Research Council dyspnoea score of 2 or higher</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Currently taking oral hypoglycaemic agent or insulin
2.	Active respiratory disease other than obstructive airways disease
3.	Exacerbation of airways disease requiring change in treatment within the preceding 6 weeks
4.	Participation in pulmonary rehabilitation programme within the past 6 weeks
5.	Currently prescribed long term oral corticosteroids
6.	Renal impairment (estimated glomerular filtration rate &lt; 45 mL/min)
7.	Cirrhosis, impaired synthetic liver function, or liver failure
8.	Chronic respiratory failure 
9.	Congestive heart failure
10.	Current or recent habitual heavy alcohol intake 
11.	Current use of antiretroviral medication
12.	Pregnancy
13.	History of lactic acidosis
14.	Allergy to metformin
15.	Unable to comply with the study procedures or protocol</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Potential subjects are identified from outpatient records.
Allocation is not concealed.</concealment>
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>N/A</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/03/2011</anticipatedstartdate>
    <actualstartdate>9/06/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>7/05/2012</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize>17</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Paul Sexton</primarysponsorname>
    <primarysponsoraddress>Department of Medicine, Building 599, Faculty of Medical &amp; Health Sciences, University of Auckland
PO Box 92019
Grafton
Auckland 1023</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Greenlane Research and Educational Fund</fundingname>
      <fundingaddress>Auckland City Hospital
Cardiology Department
Level 3, Building 32
Park Road
Grafton
AUCKLAND, 1142</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Prof John Kolbe</sponsorname>
      <sponsoraddress>Department of Medicine, Building 599, Faculty of MEdical &amp; Health Sciences, University of Auckland
PO Box 92019
Grafton
Auckland 1023</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Diabetes mellitus is known to cause damage to many organs, but its effects of the lungs are underrecognised. Diabetes is commonly associated with reduced lung volumes and impairment of other aspects of respiratory function; the cause is unknown. The effect of antidiabetic treatments on respiratory function is also largely unknown. Metformin is an oral antidiabetic agent which improves blood sugar levels and directly improves insulin resistance. Metformin is also safe for use in prediabetic and nondiabetic individuals. If metformin can improve lung function in diabetes, this could provide a way to treat diabetic and prediabetic patients with cardiorespiratory disease, as well as providing information about how diabetes affects respiratory function. We plan to evaluate the effect of 6 months of metformin treatment on lung volumes and other relevant outcomes in a group of 40 subjects with chronic obstructive pulmonary disease (COPD, emphysema) and impaired glucose tolerance or diet-controlled diabetes.</summary>
    <trialwebsite />
    <publication>Sexton P, Metcalf P, Kolbe J. Respiratory Effects of Insulin Sensitisation with Metformin: A Prospective Observational Study. COPD 2013 Jul 12. PMID: 23848509</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Y Regional Ethics Committee</ethicname>
      <ethicaddress>3rd floor, BNZ building
354 Victoria St
PO Box 1031
Hamilton</ethicaddress>
      <ethicapprovaldate>14/09/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/06/2010</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Paul Sexton</name>
      <address>Department of Medicine, Faculty of Medical &amp; Health Sciences, Building 599, University of Auckland
PO Box 92019
Grafton
Auckland 1023</address>
      <phone>+64-9-9237290</phone>
      <fax />
      <email>p.sexton@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Paul Sexton</name>
      <address>Department of Medicine, Faculty of Medical &amp; Health Sciences, Building 599, University of Auckland
PO Box 92019
Grafton
Auckland 1023</address>
      <phone>+64-9-9237290</phone>
      <fax />
      <email>p.sexton@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Paul Sexton</name>
      <address>Department of Medicine, Faculty of Medical &amp; Health Sciences, Building 599, University of Auckland PO Box 92019 Grafton Auckland 1023</address>
      <phone>+64-9-9237290</phone>
      <fax />
      <email>p.sexton@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>